两融数据显示，该股最新融资余额为14.03亿元，近5日增加5311.18万元，增幅为3.94%。（数据宝） 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为4.71亿元。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报·数据宝统计显示，君实生物-U今日收盘价为45.73元，上涨0.20%，日换手率为2.57%，成交额为9.09亿元，全天主力资金净流出3762.49万元，近5日该股累计下跌4.19%，近5日 君实生物-U9月18日大宗交易平台出现一笔成交，成交量100.00万股，成交金额4541.00万元，大宗交易成交价为45.41元，相对今日收盘价折价0.70%。该笔交易的买方营业部为方正证券股 9月18日君实生物-U大宗交易一览 ...

两融数据显示，该股最新融资余额为14.03亿元，近5日增加5311.18万元，增幅为3.94%。（数据宝） 9月18日君实生物-U大宗交易一览 君实生物-U9月18日大宗交易平台出现一笔成交，成交量100.00万股，成交金额4541.00万元，大宗交易 成交价为45.41元，相对今日收盘价折价0.70%。该笔交易的买方营业部为方正证券股份有限公司总部， 卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为4.71亿元。 证券时报·数据宝统计显示，君实生物-U今日收盘价为45.73元，上涨0.20%，日换手率为2.57%，成交额 为9.09亿元，全天主力资金净流出3762.49万元，近5日该股累计下跌4.19%，近5日资金合计净流出1.71 亿元。 | 成交量 （万 | 成交金额 | 成交价 | 相对当日收盘折 | 买方营业部 | | | --- | --- | --- | --- | --- | --- | | | （万元） | 格 | 溢价（%） | | 卖方营业部 | | 股） | | （元） | | | | | 100.00 | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 9月18日，君实生物收涨0.20%，收盘价为45.73元，发生1笔大宗交易，合计成交量100万股，成交金额 4541万元。 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为4.71亿元。该股近5个交易日累计 下跌4.19%，主力资金合计净流出1.75亿元。 责任编辑：小浪快报 第1笔成交价格为45.41元，成交100.00万股，成交金额4,541.00万元，溢价率为-0.70%，买方营业部为方 正证券股份有限公司总部，卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。 ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and other services (0.59%) [7]. Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2]. - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the U.S., EU, and Australia [2]. - Junshi is advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - The company is collaborating with various research institutions to develop vaccines, including monkeypox and Zika vaccines, which are currently in preclinical development [3]. - A partnership with Peking University and other institutions has been established to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the first half of 2025, Junshi Biosciences reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, reflecting a 36.01% increase [8]. - As of June 30, 2025, the number of shareholders increased by 5.88% to 31,200, with a decrease in average circulating shares per person by 5.56% [8]. Market Activity - On September 18, the stock price of Junshi Biosciences increased by 0.20%, with a trading volume of 909 million yuan and a turnover rate of 2.57%, resulting in a total market capitalization of 46.951 billion yuan [1]. - Recent trading activity indicates a net outflow of 31.6178 million yuan from main funds, with a lack of clear trends in main fund movements [4][5].

Core Points - The stock price of Junshi Biosciences has increased by 70.44% year-to-date, with a recent decline of 2.41% over the last five trading days [2] - The company reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, a year-on-year increase of 36.01% [2] Company Overview - Junshi Biosciences, established on December 27, 2012, is located in Shanghai and specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The main revenue sources for the company are drug sales (90.67%), technology licensing and royalties (8.74%), and technical services and others (0.59%) [2] Stock Performance and Market Activity - As of September 18, the stock price was 46.58 yuan per share, with a market capitalization of 47.823 billion yuan [1] - The trading volume on September 18 was 151 million yuan, with a turnover rate of 0.43% [1] - Institutional holdings show that the top ten circulating shareholders include various ETFs, with notable changes in shareholding [3]

9月17日，君实生物大宗交易成交100万股，成交额4532万元，占当日总成交额的6.05%，成交价45.32 元，较市场收盘价45.64元折价0.7%。 | 025-09-17 | 君实生物 | 688180 | 45.32 4532 | 100 | 方正证券股份有限 公司总部 | 中信证券股份有限 公司上海浦东新区 CALL COLLECT COLLECTION COLLECTION CONSULTER OF CLAINS | 결 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | 是否为专场 | ...

Group 1 - The Hong Kong innovative drug concept stocks experienced a significant decline on September 17, with major companies like China Biologic Products, Weiya Bio, and Fosun Pharma dropping over 4% [1] - Other companies such as Junshi Biosciences, Rongchang Biopharma, and Innovent Biologics also saw declines exceeding 3% [1]

9月16日，君实生物大宗交易成交100万股，成交额4649万元，占当日总成交额的6.79%，成交价46.49 元，较市场收盘价46.82元折价0.7%。 | 025-09-16 | 君实生制 | 081889 | 46.49 100 | 4649 | 方正证券股份有限 | 中信证券股份有限 | 증 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 蓬秀代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 公司总部 | 美出营业部 公司上海浦东新区 | 是否为专场 | ...

9月16日，君实生物盘中下跌2.00%，截至10:32，报46.48元/股，成交3.05亿元，换手率0.85%，总市值 477.21亿元。 资金流向方面，主力资金净流出1844.35万元，特大单买入2422.50万元，占比7.93%，卖出3381.70万 元，占比11.07%；大单买入8693.31万元，占比28.46%，卖出9578.46万元，占比31.36%。 君实生物所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：生物医药、H股、 增持回购、抗癌治癌、创新药等。 截至6月30日，君实生物股东户数3.12万，较上期增加5.88%；人均流通股24543股，较上期减少5.56%。 2025年1月-6月，君实生物实现营业收入11.68亿元，同比增长48.64%；归母净利润-4.13亿元，同比增长 36.01%。 机构持仓方面，截止2025年6月30日，君实生物十大流通股东中，华夏上证科创板50成份ETF （588000）位居第六大流通股东，持股2971.67万股，相比上期减少53.67万股。易方达上证科创板 50ETF（588080）位居第七大流通股东，持股2221.32万股，相比上期增加6 ...

（股份代號：1877） 於2025年9月29日（星期一）舉行之2025年第一次臨時股東大會之補充代表委任表格 重要提示：倘本公司股東尚未將臨時股東大會代表委任表格（於2025年9月5日隨（其中包括）臨時股東大會（「臨時股東大會」）通告發出）交回本公司H股股份過戶登記處，則股 東僅須交回此份補充代表委任表格，若已交回代表委任表格，則務請注意： SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） (i) H股股東於臨時股東大會指定舉行時間24小時前向本公司H股股份過戶登記處遞交的補充代表委任表格將撤銷及取替其之前遞交的代表委任表格。補充代表委任表格（若 填寫正確無誤）即視作該名H股股東遞交的有效代表委任表格及； (ii) 倘該名H股股東未能向本公司H股股份過戶登記處遞交補充代表委任表格，則已遞交的代表委任表格（若填寫正確無誤）將在最大適用範圍內維持有效。對於代表委任表 格上未載列的第9至10項新增決議案，持有代表委任表格的該名H股股東的授權代表有權自行酌情表決（倘未獲有關指示）。 本人╱吾等 （附註1） （附註 ...